Pharmacology of the new target-specific oral anticoagulants.

Article Details

Citation

Copy to clipboard

Cabral KP

Pharmacology of the new target-specific oral anticoagulants.

J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5.

PubMed ID

23645472 [ View in PubMed

]

Abstract

Oral anticoagulation therapy is transforming with the advent of the target specific oral anticoagulants, particularly, the direct thrombin inhibitors and factor Xa inhibitors. These agents have demonstrated clinical efficacy and safety and offer several potential advantages over current standard of care therapy, warfarin. Nevertheless, the pharmacology between the newly approved oral anticoagulants differs and must be considered for appropriate management and patient selection. The pharmacodynamics and pharmacokinetics of dabigatran etexilate, rivaroxaban, apixaban and edoxaban are discussed in detail, which may translate into considerable clinical implications.

DrugBank Data that Cites this Article

Drugs

Rivaroxaban

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Rivaroxaban	Cytochrome P450 3A5	Protein	Humans	Unknown	Substrate	Details